Pharma & Healthcare
Global Antibody-drug Conjugates for Tumors Market Research Report 2026
- Feb 03, 26
- ID: 694647
- Pages: 126
- Figures: 119
- Views: 4
This report delivers a comprehensive overview of the global Antibody-drug Conjugates for Tumors market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Antibody-drug Conjugates for Tumors. The Antibody-drug Conjugates for Tumors market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Antibody-drug Conjugates for Tumors market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Antibody-drug Conjugates for Tumors manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche（Genentech）
Daiichi Sankyo
GSK
Rakuten Medical
ADC Therapeutics
RemeGen
AbbVie(ImmunoGen)
Pfizer（Seagen)
Takeda
Gilead Sciences
AstraZeneca
Segment by Type
DNA Damaging Drugs
Tubulin Inhibitors
Other
by Application
Hematological Tumors
Solid Tumors
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Antibody-drug Conjugates for Tumors manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Antibody-drug Conjugates for Tumors sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Antibody-drug Conjugates for Tumors market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Antibody-drug Conjugates for Tumors manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Roche（Genentech）
Daiichi Sankyo
GSK
Rakuten Medical
ADC Therapeutics
RemeGen
AbbVie(ImmunoGen)
Pfizer（Seagen)
Takeda
Gilead Sciences
AstraZeneca
Segment by Type
DNA Damaging Drugs
Tubulin Inhibitors
Other
by Application
Hematological Tumors
Solid Tumors
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Antibody-drug Conjugates for Tumors manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Antibody-drug Conjugates for Tumors sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Antibody-drug Conjugates for Tumors Market Overview
1.1 Product Definition
1.2 Antibody-drug Conjugates for Tumors by Type
1.2.1 Global Antibody-drug Conjugates for Tumors Market Value by Type: 2025 vs 2032
1.2.2 DNA Damaging Drugs
1.2.3 Tubulin Inhibitors
1.2.4 Other
1.3 Antibody-drug Conjugates for Tumors by Application
1.3.1 Global Antibody-drug Conjugates for Tumors Market Value by Application: 2025 vs 2032
1.3.2 Hematological Tumors
1.3.3 Solid Tumors
1.4 Global Antibody-drug Conjugates for Tumors Market Size Estimates and Forecasts
1.4.1 Global Antibody-drug Conjugates for Tumors Revenue 2021–2032
1.4.2 Global Antibody-drug Conjugates for Tumors Sales 2021–2032
1.4.3 Global Antibody-drug Conjugates for Tumors Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Antibody-drug Conjugates for Tumors Market Competition by Manufacturers
2.1 Global Antibody-drug Conjugates for Tumors Sales Market Share by Manufacturers (2021–2026)
2.2 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Antibody-drug Conjugates for Tumors Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Antibody-drug Conjugates for Tumors, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Product Types and Applications
2.7 Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Date of Entry into the Industry
2.8 Global Antibody-drug Conjugates for Tumors Market Competitive Situation and Trends
2.8.1 Global Antibody-drug Conjugates for Tumors Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Antibody-drug Conjugates for Tumors Players Market Share by Revenue
2.8.3 Global Antibody-drug Conjugates for Tumors Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antibody-drug Conjugates for Tumors Market Scenario by Region
3.1 Global Antibody-drug Conjugates for Tumors Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Antibody-drug Conjugates for Tumors Sales by Region: 2021–2032
3.2.1 Global Antibody-drug Conjugates for Tumors Sales by Region: 2021–2026
3.2.2 Global Antibody-drug Conjugates for Tumors Sales by Region: 2027–2032
3.3 Global Antibody-drug Conjugates for Tumors Revenue by Region: 2021–2032
3.3.1 Global Antibody-drug Conjugates for Tumors Revenue by Region: 2021–2026
3.3.2 Global Antibody-drug Conjugates for Tumors Revenue by Region: 2027–2032
3.4 North America Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
3.4.1 North America Antibody-drug Conjugates for Tumors Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Antibody-drug Conjugates for Tumors Sales by Country (2021–2032)
3.4.3 North America Antibody-drug Conjugates for Tumors Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
3.5.1 Europe Antibody-drug Conjugates for Tumors Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Antibody-drug Conjugates for Tumors Sales by Country (2021–2032)
3.5.3 Europe Antibody-drug Conjugates for Tumors Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antibody-drug Conjugates for Tumors Market Facts & Figures by Region
3.6.1 Asia Pacific Antibody-drug Conjugates for Tumors Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Antibody-drug Conjugates for Tumors Sales by Region (2021–2032)
3.6.3 Asia Pacific Antibody-drug Conjugates for Tumors Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
3.7.1 Latin America Antibody-drug Conjugates for Tumors Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Antibody-drug Conjugates for Tumors Sales by Country (2021–2032)
3.7.3 Latin America Antibody-drug Conjugates for Tumors Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
3.8.1 Middle East and Africa Antibody-drug Conjugates for Tumors Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Antibody-drug Conjugates for Tumors Sales by Country (2021–2032)
3.8.3 Middle East and Africa Antibody-drug Conjugates for Tumors Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antibody-drug Conjugates for Tumors Sales by Type (2021–2032)
4.1.1 Global Antibody-drug Conjugates for Tumors Sales by Type (2021–2026)
4.1.2 Global Antibody-drug Conjugates for Tumors Sales by Type (2027–2032)
4.1.3 Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2021–2032)
4.2 Global Antibody-drug Conjugates for Tumors Revenue by Type (2021–2032)
4.2.1 Global Antibody-drug Conjugates for Tumors Revenue by Type (2021–2026)
4.2.2 Global Antibody-drug Conjugates for Tumors Revenue by Type (2027–2032)
4.2.3 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2021–2032)
4.3 Global Antibody-drug Conjugates for Tumors Price by Type (2021–2032)
5 Segment by Application
5.1 Global Antibody-drug Conjugates for Tumors Sales by Application (2021–2032)
5.1.1 Global Antibody-drug Conjugates for Tumors Sales by Application (2021–2026)
5.1.2 Global Antibody-drug Conjugates for Tumors Sales by Application (2027–2032)
5.1.3 Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2021–2032)
5.2 Global Antibody-drug Conjugates for Tumors Revenue by Application (2021–2032)
5.2.1 Global Antibody-drug Conjugates for Tumors Revenue by Application (2021–2026)
5.2.2 Global Antibody-drug Conjugates for Tumors Revenue by Application (2027–2032)
5.2.3 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2021–2032)
5.3 Global Antibody-drug Conjugates for Tumors Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche（Genentech）
6.1.1 Roche（Genentech） Company Information
6.1.2 Roche（Genentech） Description and Business Overview
6.1.3 Roche（Genentech） Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche（Genentech） Antibody-drug Conjugates for Tumors Product Portfolio
6.1.5 Roche（Genentech） Recent Developments/Updates
6.2 Daiichi Sankyo
6.2.1 Daiichi Sankyo Company Information
6.2.2 Daiichi Sankyo Description and Business Overview
6.2.3 Daiichi Sankyo Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Daiichi Sankyo Antibody-drug Conjugates for Tumors Product Portfolio
6.2.5 Daiichi Sankyo Recent Developments/Updates
6.3 GSK
6.3.1 GSK Company Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 GSK Antibody-drug Conjugates for Tumors Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Rakuten Medical
6.4.1 Rakuten Medical Company Information
6.4.2 Rakuten Medical Description and Business Overview
6.4.3 Rakuten Medical Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Rakuten Medical Antibody-drug Conjugates for Tumors Product Portfolio
6.4.5 Rakuten Medical Recent Developments/Updates
6.5 ADC Therapeutics
6.5.1 ADC Therapeutics Company Information
6.5.2 ADC Therapeutics Description and Business Overview
6.5.3 ADC Therapeutics Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 ADC Therapeutics Antibody-drug Conjugates for Tumors Product Portfolio
6.5.5 ADC Therapeutics Recent Developments/Updates
6.6 RemeGen
6.6.1 RemeGen Company Information
6.6.2 RemeGen Description and Business Overview
6.6.3 RemeGen Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 RemeGen Antibody-drug Conjugates for Tumors Product Portfolio
6.6.5 RemeGen Recent Developments/Updates
6.7 AbbVie(ImmunoGen)
6.7.1 AbbVie(ImmunoGen) Company Information
6.7.2 AbbVie(ImmunoGen) Description and Business Overview
6.7.3 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Product Portfolio
6.7.5 AbbVie(ImmunoGen) Recent Developments/Updates
6.8 Pfizer（Seagen)
6.8.1 Pfizer（Seagen) Company Information
6.8.2 Pfizer（Seagen) Description and Business Overview
6.8.3 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Product Portfolio
6.8.5 Pfizer（Seagen) Recent Developments/Updates
6.9 Takeda
6.9.1 Takeda Company Information
6.9.2 Takeda Description and Business Overview
6.9.3 Takeda Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Takeda Antibody-drug Conjugates for Tumors Product Portfolio
6.9.5 Takeda Recent Developments/Updates
6.10 Gilead Sciences
6.10.1 Gilead Sciences Company Information
6.10.2 Gilead Sciences Description and Business Overview
6.10.3 Gilead Sciences Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Gilead Sciences Antibody-drug Conjugates for Tumors Product Portfolio
6.10.5 Gilead Sciences Recent Developments/Updates
6.11 AstraZeneca
6.11.1 AstraZeneca Company Information
6.11.2 AstraZeneca Description and Business Overview
6.11.3 AstraZeneca Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 AstraZeneca Antibody-drug Conjugates for Tumors Product Portfolio
6.11.5 AstraZeneca Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antibody-drug Conjugates for Tumors Industry Chain Analysis
7.2 Antibody-drug Conjugates for Tumors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antibody-drug Conjugates for Tumors Production Mode & Process Analysis
7.4 Antibody-drug Conjugates for Tumors Sales and Marketing
7.4.1 Antibody-drug Conjugates for Tumors Sales Channels
7.4.2 Antibody-drug Conjugates for Tumors Distributors
7.5 Antibody-drug Conjugates for Tumors Customer Analysis
8 Antibody-drug Conjugates for Tumors Market Dynamics
8.1 Antibody-drug Conjugates for Tumors Industry Trends
8.2 Antibody-drug Conjugates for Tumors Market Drivers
8.3 Antibody-drug Conjugates for Tumors Market Challenges
8.4 Antibody-drug Conjugates for Tumors Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Antibody-drug Conjugates for Tumors by Type
1.2.1 Global Antibody-drug Conjugates for Tumors Market Value by Type: 2025 vs 2032
1.2.2 DNA Damaging Drugs
1.2.3 Tubulin Inhibitors
1.2.4 Other
1.3 Antibody-drug Conjugates for Tumors by Application
1.3.1 Global Antibody-drug Conjugates for Tumors Market Value by Application: 2025 vs 2032
1.3.2 Hematological Tumors
1.3.3 Solid Tumors
1.4 Global Antibody-drug Conjugates for Tumors Market Size Estimates and Forecasts
1.4.1 Global Antibody-drug Conjugates for Tumors Revenue 2021–2032
1.4.2 Global Antibody-drug Conjugates for Tumors Sales 2021–2032
1.4.3 Global Antibody-drug Conjugates for Tumors Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Antibody-drug Conjugates for Tumors Market Competition by Manufacturers
2.1 Global Antibody-drug Conjugates for Tumors Sales Market Share by Manufacturers (2021–2026)
2.2 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Antibody-drug Conjugates for Tumors Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Antibody-drug Conjugates for Tumors, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Product Types and Applications
2.7 Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Date of Entry into the Industry
2.8 Global Antibody-drug Conjugates for Tumors Market Competitive Situation and Trends
2.8.1 Global Antibody-drug Conjugates for Tumors Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Antibody-drug Conjugates for Tumors Players Market Share by Revenue
2.8.3 Global Antibody-drug Conjugates for Tumors Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Antibody-drug Conjugates for Tumors Market Scenario by Region
3.1 Global Antibody-drug Conjugates for Tumors Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Antibody-drug Conjugates for Tumors Sales by Region: 2021–2032
3.2.1 Global Antibody-drug Conjugates for Tumors Sales by Region: 2021–2026
3.2.2 Global Antibody-drug Conjugates for Tumors Sales by Region: 2027–2032
3.3 Global Antibody-drug Conjugates for Tumors Revenue by Region: 2021–2032
3.3.1 Global Antibody-drug Conjugates for Tumors Revenue by Region: 2021–2026
3.3.2 Global Antibody-drug Conjugates for Tumors Revenue by Region: 2027–2032
3.4 North America Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
3.4.1 North America Antibody-drug Conjugates for Tumors Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Antibody-drug Conjugates for Tumors Sales by Country (2021–2032)
3.4.3 North America Antibody-drug Conjugates for Tumors Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
3.5.1 Europe Antibody-drug Conjugates for Tumors Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Antibody-drug Conjugates for Tumors Sales by Country (2021–2032)
3.5.3 Europe Antibody-drug Conjugates for Tumors Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antibody-drug Conjugates for Tumors Market Facts & Figures by Region
3.6.1 Asia Pacific Antibody-drug Conjugates for Tumors Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Antibody-drug Conjugates for Tumors Sales by Region (2021–2032)
3.6.3 Asia Pacific Antibody-drug Conjugates for Tumors Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
3.7.1 Latin America Antibody-drug Conjugates for Tumors Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Antibody-drug Conjugates for Tumors Sales by Country (2021–2032)
3.7.3 Latin America Antibody-drug Conjugates for Tumors Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Antibody-drug Conjugates for Tumors Market Facts & Figures by Country
3.8.1 Middle East and Africa Antibody-drug Conjugates for Tumors Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Antibody-drug Conjugates for Tumors Sales by Country (2021–2032)
3.8.3 Middle East and Africa Antibody-drug Conjugates for Tumors Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Antibody-drug Conjugates for Tumors Sales by Type (2021–2032)
4.1.1 Global Antibody-drug Conjugates for Tumors Sales by Type (2021–2026)
4.1.2 Global Antibody-drug Conjugates for Tumors Sales by Type (2027–2032)
4.1.3 Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2021–2032)
4.2 Global Antibody-drug Conjugates for Tumors Revenue by Type (2021–2032)
4.2.1 Global Antibody-drug Conjugates for Tumors Revenue by Type (2021–2026)
4.2.2 Global Antibody-drug Conjugates for Tumors Revenue by Type (2027–2032)
4.2.3 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2021–2032)
4.3 Global Antibody-drug Conjugates for Tumors Price by Type (2021–2032)
5 Segment by Application
5.1 Global Antibody-drug Conjugates for Tumors Sales by Application (2021–2032)
5.1.1 Global Antibody-drug Conjugates for Tumors Sales by Application (2021–2026)
5.1.2 Global Antibody-drug Conjugates for Tumors Sales by Application (2027–2032)
5.1.3 Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2021–2032)
5.2 Global Antibody-drug Conjugates for Tumors Revenue by Application (2021–2032)
5.2.1 Global Antibody-drug Conjugates for Tumors Revenue by Application (2021–2026)
5.2.2 Global Antibody-drug Conjugates for Tumors Revenue by Application (2027–2032)
5.2.3 Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2021–2032)
5.3 Global Antibody-drug Conjugates for Tumors Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Roche（Genentech）
6.1.1 Roche（Genentech） Company Information
6.1.2 Roche（Genentech） Description and Business Overview
6.1.3 Roche（Genentech） Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Roche（Genentech） Antibody-drug Conjugates for Tumors Product Portfolio
6.1.5 Roche（Genentech） Recent Developments/Updates
6.2 Daiichi Sankyo
6.2.1 Daiichi Sankyo Company Information
6.2.2 Daiichi Sankyo Description and Business Overview
6.2.3 Daiichi Sankyo Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Daiichi Sankyo Antibody-drug Conjugates for Tumors Product Portfolio
6.2.5 Daiichi Sankyo Recent Developments/Updates
6.3 GSK
6.3.1 GSK Company Information
6.3.2 GSK Description and Business Overview
6.3.3 GSK Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 GSK Antibody-drug Conjugates for Tumors Product Portfolio
6.3.5 GSK Recent Developments/Updates
6.4 Rakuten Medical
6.4.1 Rakuten Medical Company Information
6.4.2 Rakuten Medical Description and Business Overview
6.4.3 Rakuten Medical Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Rakuten Medical Antibody-drug Conjugates for Tumors Product Portfolio
6.4.5 Rakuten Medical Recent Developments/Updates
6.5 ADC Therapeutics
6.5.1 ADC Therapeutics Company Information
6.5.2 ADC Therapeutics Description and Business Overview
6.5.3 ADC Therapeutics Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.5.4 ADC Therapeutics Antibody-drug Conjugates for Tumors Product Portfolio
6.5.5 ADC Therapeutics Recent Developments/Updates
6.6 RemeGen
6.6.1 RemeGen Company Information
6.6.2 RemeGen Description and Business Overview
6.6.3 RemeGen Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.6.4 RemeGen Antibody-drug Conjugates for Tumors Product Portfolio
6.6.5 RemeGen Recent Developments/Updates
6.7 AbbVie(ImmunoGen)
6.7.1 AbbVie(ImmunoGen) Company Information
6.7.2 AbbVie(ImmunoGen) Description and Business Overview
6.7.3 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.7.4 AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Product Portfolio
6.7.5 AbbVie(ImmunoGen) Recent Developments/Updates
6.8 Pfizer（Seagen)
6.8.1 Pfizer（Seagen) Company Information
6.8.2 Pfizer（Seagen) Description and Business Overview
6.8.3 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.8.4 Pfizer（Seagen) Antibody-drug Conjugates for Tumors Product Portfolio
6.8.5 Pfizer（Seagen) Recent Developments/Updates
6.9 Takeda
6.9.1 Takeda Company Information
6.9.2 Takeda Description and Business Overview
6.9.3 Takeda Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.9.4 Takeda Antibody-drug Conjugates for Tumors Product Portfolio
6.9.5 Takeda Recent Developments/Updates
6.10 Gilead Sciences
6.10.1 Gilead Sciences Company Information
6.10.2 Gilead Sciences Description and Business Overview
6.10.3 Gilead Sciences Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.10.4 Gilead Sciences Antibody-drug Conjugates for Tumors Product Portfolio
6.10.5 Gilead Sciences Recent Developments/Updates
6.11 AstraZeneca
6.11.1 AstraZeneca Company Information
6.11.2 AstraZeneca Description and Business Overview
6.11.3 AstraZeneca Antibody-drug Conjugates for Tumors Sales, Revenue, and Gross Margin (2021–2026)
6.11.4 AstraZeneca Antibody-drug Conjugates for Tumors Product Portfolio
6.11.5 AstraZeneca Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Antibody-drug Conjugates for Tumors Industry Chain Analysis
7.2 Antibody-drug Conjugates for Tumors Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antibody-drug Conjugates for Tumors Production Mode & Process Analysis
7.4 Antibody-drug Conjugates for Tumors Sales and Marketing
7.4.1 Antibody-drug Conjugates for Tumors Sales Channels
7.4.2 Antibody-drug Conjugates for Tumors Distributors
7.5 Antibody-drug Conjugates for Tumors Customer Analysis
8 Antibody-drug Conjugates for Tumors Market Dynamics
8.1 Antibody-drug Conjugates for Tumors Industry Trends
8.2 Antibody-drug Conjugates for Tumors Market Drivers
8.3 Antibody-drug Conjugates for Tumors Market Challenges
8.4 Antibody-drug Conjugates for Tumors Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Antibody-drug Conjugates for Tumors Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Antibody-drug Conjugates for Tumors Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Antibody-drug Conjugates for Tumors Market Competitive Situation by Manufacturers in 2025
Table 4. Global Antibody-drug Conjugates for Tumors Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Antibody-drug Conjugates for Tumors Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Antibody-drug Conjugates for Tumors Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Antibody-drug Conjugates for Tumors Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Antibody-drug Conjugates for Tumors Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Antibody-drug Conjugates for Tumors, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Product Types and Applications
Table 12. Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antibody-drug Conjugates for Tumors Companies by Tier (Tier 1, Tier 2, Tier 3), based on Antibody-drug Conjugates for Tumors Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antibody-drug Conjugates for Tumors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Antibody-drug Conjugates for Tumors Sales by Region (K Units), 2021–2026
Table 18. Global Antibody-drug Conjugates for Tumors Sales Market Share by Region (2021–2026)
Table 19. Global Antibody-drug Conjugates for Tumors Sales by Region (K Units), 2027–2032
Table 20. Global Antibody-drug Conjugates for Tumors Sales Market Share by Region (2027–2032)
Table 21. Global Antibody-drug Conjugates for Tumors Revenue by Region (US$ Million), 2021–2026
Table 22. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021–2026)
Table 23. Global Antibody-drug Conjugates for Tumors Revenue by Region (US$ Million), 2027–2032
Table 24. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2027–2032)
Table 25. North America Antibody-drug Conjugates for Tumors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2021–2026
Table 27. North America Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2027–2032
Table 28. North America Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2021–2026
Table 29. North America Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Antibody-drug Conjugates for Tumors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2021–2026
Table 32. Europe Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2027–2032
Table 33. Europe Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Antibody-drug Conjugates for Tumors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Antibody-drug Conjugates for Tumors Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Antibody-drug Conjugates for Tumors Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Antibody-drug Conjugates for Tumors Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Antibody-drug Conjugates for Tumors Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Antibody-drug Conjugates for Tumors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2021–2026
Table 42. Latin America Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2027–2032
Table 43. Latin America Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Antibody-drug Conjugates for Tumors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2027–2032
Table 50. Global Antibody-drug Conjugates for Tumors Sales (K Units) by Type (2021–2026)
Table 51. Global Antibody-drug Conjugates for Tumors Sales (K Units) by Type (2027–2032)
Table 52. Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2021–2026)
Table 53. Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2027–2032)
Table 54. Global Antibody-drug Conjugates for Tumors Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Antibody-drug Conjugates for Tumors Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2021–2026)
Table 57. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2027–2032)
Table 58. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Type (2021–2026)
Table 59. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Type (2027–2032)
Table 60. Global Antibody-drug Conjugates for Tumors Sales (K Units) by Application (2021–2026)
Table 61. Global Antibody-drug Conjugates for Tumors Sales (K Units) by Application (2027–2032)
Table 62. Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2021–2026)
Table 63. Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2027–2032)
Table 64. Global Antibody-drug Conjugates for Tumors Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Antibody-drug Conjugates for Tumors Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2021–2026)
Table 67. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2027–2032)
Table 68. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Application (2021–2026)
Table 69. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Application (2027–2032)
Table 70. Roche（Genentech） Company Information
Table 71. Roche（Genentech） Description and Business Overview
Table 72. Roche（Genentech） Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche（Genentech） Antibody-drug Conjugates for Tumors Product
Table 74. Roche（Genentech） Recent Developments/Updates
Table 75. Daiichi Sankyo Company Information
Table 76. Daiichi Sankyo Description and Business Overview
Table 77. Daiichi Sankyo Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Daiichi Sankyo Antibody-drug Conjugates for Tumors Product
Table 79. Daiichi Sankyo Recent Developments/Updates
Table 80. GSK Company Information
Table 81. GSK Description and Business Overview
Table 82. GSK Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. GSK Antibody-drug Conjugates for Tumors Product
Table 84. GSK Recent Developments/Updates
Table 85. Rakuten Medical Company Information
Table 86. Rakuten Medical Description and Business Overview
Table 87. Rakuten Medical Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Rakuten Medical Antibody-drug Conjugates for Tumors Product
Table 89. Rakuten Medical Recent Developments/Updates
Table 90. ADC Therapeutics Company Information
Table 91. ADC Therapeutics Description and Business Overview
Table 92. ADC Therapeutics Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. ADC Therapeutics Antibody-drug Conjugates for Tumors Product
Table 94. ADC Therapeutics Recent Developments/Updates
Table 95. RemeGen Company Information
Table 96. RemeGen Description and Business Overview
Table 97. RemeGen Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. RemeGen Antibody-drug Conjugates for Tumors Product
Table 99. RemeGen Recent Developments/Updates
Table 100. AbbVie(ImmunoGen) Company Information
Table 101. AbbVie(ImmunoGen) Description and Business Overview
Table 102. AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Product
Table 104. AbbVie(ImmunoGen) Recent Developments/Updates
Table 105. Pfizer（Seagen) Company Information
Table 106. Pfizer（Seagen) Description and Business Overview
Table 107. Pfizer（Seagen) Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Pfizer（Seagen) Antibody-drug Conjugates for Tumors Product
Table 109. Pfizer（Seagen) Recent Developments/Updates
Table 110. Takeda Company Information
Table 111. Takeda Description and Business Overview
Table 112. Takeda Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Takeda Antibody-drug Conjugates for Tumors Product
Table 114. Takeda Recent Developments/Updates
Table 115. Gilead Sciences Company Information
Table 116. Gilead Sciences Description and Business Overview
Table 117. Gilead Sciences Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Gilead Sciences Antibody-drug Conjugates for Tumors Product
Table 119. Gilead Sciences Recent Developments/Updates
Table 120. AstraZeneca Company Information
Table 121. AstraZeneca Description and Business Overview
Table 122. AstraZeneca Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. AstraZeneca Antibody-drug Conjugates for Tumors Product
Table 124. AstraZeneca Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Antibody-drug Conjugates for Tumors Distributors List
Table 128. Antibody-drug Conjugates for Tumors Customers List
Table 129. Antibody-drug Conjugates for Tumors Market Trends
Table 130. Antibody-drug Conjugates for Tumors Market Drivers
Table 131. Antibody-drug Conjugates for Tumors Market Challenges
Table 132. Antibody-drug Conjugates for Tumors Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of Antibody-drug Conjugates for Tumors
Figure 2. Global Antibody-drug Conjugates for Tumors Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Antibody-drug Conjugates for Tumors Market Share by Type: 2025 & 2032
Figure 4. DNA Damaging Drugs Product Picture
Figure 5. Tubulin Inhibitors Product Picture
Figure 6. Other Product Picture
Figure 7. Global Antibody-drug Conjugates for Tumors Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Antibody-drug Conjugates for Tumors Market Share by Application: 2025 & 2032
Figure 9. Hematological Tumors
Figure 10. Solid Tumors
Figure 11. Global Antibody-drug Conjugates for Tumors Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Antibody-drug Conjugates for Tumors Market Size (US$ Million), 2021–2032
Figure 13. Global Antibody-drug Conjugates for Tumors Sales (K Units), 2021–2032
Figure 14. Global Antibody-drug Conjugates for Tumors Average Price (US$/Unit), 2021–2032
Figure 15. Antibody-drug Conjugates for Tumors Report Years Considered
Figure 16. Antibody-drug Conjugates for Tumors Sales Share by Manufacturers in 2025
Figure 17. Global Antibody-drug Conjugates for Tumors Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Antibody-drug Conjugates for Tumors Players: Market Share by Revenue in Antibody-drug Conjugates for Tumors in 2025
Figure 19. Antibody-drug Conjugates for Tumors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Antibody-drug Conjugates for Tumors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021–2032)
Figure 22. North America Antibody-drug Conjugates for Tumors Revenue Market Share by Country (2021–2032)
Figure 23. United States Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021–2032)
Figure 26. Europe Antibody-drug Conjugates for Tumors Revenue Market Share by Country (2021–2032)
Figure 27. Germany Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Antibody-drug Conjugates for Tumors Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021–2032)
Figure 34. China Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021–2032)
Figure 42. Latin America Antibody-drug Conjugates for Tumors Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Antibody-drug Conjugates for Tumors Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Antibody-drug Conjugates for Tumors by Type (2021–2032)
Figure 53. Global Revenue Market Share of Antibody-drug Conjugates for Tumors by Type (2021–2032)
Figure 54. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Antibody-drug Conjugates for Tumors by Application (2021–2032)
Figure 56. Global Revenue Market Share of Antibody-drug Conjugates for Tumors by Application (2021–2032)
Figure 57. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Application (2021–2032)
Figure 58. Antibody-drug Conjugates for Tumors Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Antibody-drug Conjugates for Tumors Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Antibody-drug Conjugates for Tumors Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Antibody-drug Conjugates for Tumors Market Competitive Situation by Manufacturers in 2025
Table 4. Global Antibody-drug Conjugates for Tumors Sales (K Units) of Key Manufacturers (2021–2026)
Table 5. Global Antibody-drug Conjugates for Tumors Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Antibody-drug Conjugates for Tumors Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Antibody-drug Conjugates for Tumors Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Antibody-drug Conjugates for Tumors Average Price (US$/Unit) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Antibody-drug Conjugates for Tumors, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Product Types and Applications
Table 12. Global Key Manufacturers of Antibody-drug Conjugates for Tumors, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antibody-drug Conjugates for Tumors Companies by Tier (Tier 1, Tier 2, Tier 3), based on Antibody-drug Conjugates for Tumors Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antibody-drug Conjugates for Tumors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Antibody-drug Conjugates for Tumors Sales by Region (K Units), 2021–2026
Table 18. Global Antibody-drug Conjugates for Tumors Sales Market Share by Region (2021–2026)
Table 19. Global Antibody-drug Conjugates for Tumors Sales by Region (K Units), 2027–2032
Table 20. Global Antibody-drug Conjugates for Tumors Sales Market Share by Region (2027–2032)
Table 21. Global Antibody-drug Conjugates for Tumors Revenue by Region (US$ Million), 2021–2026
Table 22. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021–2026)
Table 23. Global Antibody-drug Conjugates for Tumors Revenue by Region (US$ Million), 2027–2032
Table 24. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2027–2032)
Table 25. North America Antibody-drug Conjugates for Tumors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2021–2026
Table 27. North America Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2027–2032
Table 28. North America Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2021–2026
Table 29. North America Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Antibody-drug Conjugates for Tumors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2021–2026
Table 32. Europe Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2027–2032
Table 33. Europe Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Antibody-drug Conjugates for Tumors Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Antibody-drug Conjugates for Tumors Sales by Region (K Units), 2021–2026
Table 37. Asia Pacific Antibody-drug Conjugates for Tumors Sales by Region (K Units), 2027–2032
Table 38. Asia Pacific Antibody-drug Conjugates for Tumors Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Antibody-drug Conjugates for Tumors Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Antibody-drug Conjugates for Tumors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2021–2026
Table 42. Latin America Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2027–2032
Table 43. Latin America Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Antibody-drug Conjugates for Tumors Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2021–2026
Table 47. Middle East and Africa Antibody-drug Conjugates for Tumors Sales by Country (K Units), 2027–2032
Table 48. Middle East and Africa Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Antibody-drug Conjugates for Tumors Revenue by Country (US$ Million), 2027–2032
Table 50. Global Antibody-drug Conjugates for Tumors Sales (K Units) by Type (2021–2026)
Table 51. Global Antibody-drug Conjugates for Tumors Sales (K Units) by Type (2027–2032)
Table 52. Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2021–2026)
Table 53. Global Antibody-drug Conjugates for Tumors Sales Market Share by Type (2027–2032)
Table 54. Global Antibody-drug Conjugates for Tumors Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Antibody-drug Conjugates for Tumors Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2021–2026)
Table 57. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Type (2027–2032)
Table 58. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Type (2021–2026)
Table 59. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Type (2027–2032)
Table 60. Global Antibody-drug Conjugates for Tumors Sales (K Units) by Application (2021–2026)
Table 61. Global Antibody-drug Conjugates for Tumors Sales (K Units) by Application (2027–2032)
Table 62. Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2021–2026)
Table 63. Global Antibody-drug Conjugates for Tumors Sales Market Share by Application (2027–2032)
Table 64. Global Antibody-drug Conjugates for Tumors Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Antibody-drug Conjugates for Tumors Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2021–2026)
Table 67. Global Antibody-drug Conjugates for Tumors Revenue Market Share by Application (2027–2032)
Table 68. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Application (2021–2026)
Table 69. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Application (2027–2032)
Table 70. Roche（Genentech） Company Information
Table 71. Roche（Genentech） Description and Business Overview
Table 72. Roche（Genentech） Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 73. Roche（Genentech） Antibody-drug Conjugates for Tumors Product
Table 74. Roche（Genentech） Recent Developments/Updates
Table 75. Daiichi Sankyo Company Information
Table 76. Daiichi Sankyo Description and Business Overview
Table 77. Daiichi Sankyo Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 78. Daiichi Sankyo Antibody-drug Conjugates for Tumors Product
Table 79. Daiichi Sankyo Recent Developments/Updates
Table 80. GSK Company Information
Table 81. GSK Description and Business Overview
Table 82. GSK Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 83. GSK Antibody-drug Conjugates for Tumors Product
Table 84. GSK Recent Developments/Updates
Table 85. Rakuten Medical Company Information
Table 86. Rakuten Medical Description and Business Overview
Table 87. Rakuten Medical Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 88. Rakuten Medical Antibody-drug Conjugates for Tumors Product
Table 89. Rakuten Medical Recent Developments/Updates
Table 90. ADC Therapeutics Company Information
Table 91. ADC Therapeutics Description and Business Overview
Table 92. ADC Therapeutics Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 93. ADC Therapeutics Antibody-drug Conjugates for Tumors Product
Table 94. ADC Therapeutics Recent Developments/Updates
Table 95. RemeGen Company Information
Table 96. RemeGen Description and Business Overview
Table 97. RemeGen Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 98. RemeGen Antibody-drug Conjugates for Tumors Product
Table 99. RemeGen Recent Developments/Updates
Table 100. AbbVie(ImmunoGen) Company Information
Table 101. AbbVie(ImmunoGen) Description and Business Overview
Table 102. AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 103. AbbVie(ImmunoGen) Antibody-drug Conjugates for Tumors Product
Table 104. AbbVie(ImmunoGen) Recent Developments/Updates
Table 105. Pfizer（Seagen) Company Information
Table 106. Pfizer（Seagen) Description and Business Overview
Table 107. Pfizer（Seagen) Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 108. Pfizer（Seagen) Antibody-drug Conjugates for Tumors Product
Table 109. Pfizer（Seagen) Recent Developments/Updates
Table 110. Takeda Company Information
Table 111. Takeda Description and Business Overview
Table 112. Takeda Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 113. Takeda Antibody-drug Conjugates for Tumors Product
Table 114. Takeda Recent Developments/Updates
Table 115. Gilead Sciences Company Information
Table 116. Gilead Sciences Description and Business Overview
Table 117. Gilead Sciences Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 118. Gilead Sciences Antibody-drug Conjugates for Tumors Product
Table 119. Gilead Sciences Recent Developments/Updates
Table 120. AstraZeneca Company Information
Table 121. AstraZeneca Description and Business Overview
Table 122. AstraZeneca Antibody-drug Conjugates for Tumors Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)
Table 123. AstraZeneca Antibody-drug Conjugates for Tumors Product
Table 124. AstraZeneca Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Antibody-drug Conjugates for Tumors Distributors List
Table 128. Antibody-drug Conjugates for Tumors Customers List
Table 129. Antibody-drug Conjugates for Tumors Market Trends
Table 130. Antibody-drug Conjugates for Tumors Market Drivers
Table 131. Antibody-drug Conjugates for Tumors Market Challenges
Table 132. Antibody-drug Conjugates for Tumors Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 136. Authors List of This Report
List of Figures
Figure 1. Product Picture of Antibody-drug Conjugates for Tumors
Figure 2. Global Antibody-drug Conjugates for Tumors Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Antibody-drug Conjugates for Tumors Market Share by Type: 2025 & 2032
Figure 4. DNA Damaging Drugs Product Picture
Figure 5. Tubulin Inhibitors Product Picture
Figure 6. Other Product Picture
Figure 7. Global Antibody-drug Conjugates for Tumors Market Value by Application (US$ Million), 2021–2032
Figure 8. Global Antibody-drug Conjugates for Tumors Market Share by Application: 2025 & 2032
Figure 9. Hematological Tumors
Figure 10. Solid Tumors
Figure 11. Global Antibody-drug Conjugates for Tumors Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Antibody-drug Conjugates for Tumors Market Size (US$ Million), 2021–2032
Figure 13. Global Antibody-drug Conjugates for Tumors Sales (K Units), 2021–2032
Figure 14. Global Antibody-drug Conjugates for Tumors Average Price (US$/Unit), 2021–2032
Figure 15. Antibody-drug Conjugates for Tumors Report Years Considered
Figure 16. Antibody-drug Conjugates for Tumors Sales Share by Manufacturers in 2025
Figure 17. Global Antibody-drug Conjugates for Tumors Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Antibody-drug Conjugates for Tumors Players: Market Share by Revenue in Antibody-drug Conjugates for Tumors in 2025
Figure 19. Antibody-drug Conjugates for Tumors Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Antibody-drug Conjugates for Tumors Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021–2032)
Figure 22. North America Antibody-drug Conjugates for Tumors Revenue Market Share by Country (2021–2032)
Figure 23. United States Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021–2032)
Figure 26. Europe Antibody-drug Conjugates for Tumors Revenue Market Share by Country (2021–2032)
Figure 27. Germany Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Antibody-drug Conjugates for Tumors Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Antibody-drug Conjugates for Tumors Revenue Market Share by Region (2021–2032)
Figure 34. China Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021–2032)
Figure 42. Latin America Antibody-drug Conjugates for Tumors Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Antibody-drug Conjugates for Tumors Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Antibody-drug Conjugates for Tumors Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Antibody-drug Conjugates for Tumors Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Antibody-drug Conjugates for Tumors by Type (2021–2032)
Figure 53. Global Revenue Market Share of Antibody-drug Conjugates for Tumors by Type (2021–2032)
Figure 54. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Type (2021–2032)
Figure 55. Global Sales Market Share of Antibody-drug Conjugates for Tumors by Application (2021–2032)
Figure 56. Global Revenue Market Share of Antibody-drug Conjugates for Tumors by Application (2021–2032)
Figure 57. Global Antibody-drug Conjugates for Tumors Price (US$/Unit) by Application (2021–2032)
Figure 58. Antibody-drug Conjugates for Tumors Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Sales Planning Tool Market Research Report 2026
Feb 03, 26
Global Chromium Oxide Powder Market Research Report 2026
Feb 03, 26
Global Shape Memory Actuator Market Research Report 2026
Feb 03, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232